November 17th 2024
At the 2024 SDPA Fall Conference, Hilary Baldwin, MD, highlighted innovative strategies for managing complex rosacea cases, the importance of combination approaches, and a slowing treatment pipeline.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
New Drugs and Therapies in 2022: Acne, Rosacea, and Pruritus
January 24th 2022Patients suffering from several dermatologic diseases and conditions including acne, rosacea, and pruritus can largely benefit from the new and exciting therapies and treatment modalities that have recently become available.
Full Pipeline, Customized Diagnoses Expand Options for Rosacea
September 8th 2021Challenges with overlaps in diagnosis and classification based on rosacea’s 4 subtypes are creating a new focus on features of the condition in each patient. A pipeline of new drugs awaiting FDA approvals could further expand options.
Neuromodulators Combat Key Rosacea Challenges
April 22nd 2021In treatments addressing muscular contraction, botulinum toxin inhibits nerves that innervate blood vessels from releasing acetylcholine, which triggers vasodilation. Its impact on the innate immune system suggests that botulinum toxin may also help reduce recalcitrant rosacea-related papules and pustules.